Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Bone Drug Xgeva Delays Pain From Prostate Cancer Metastases

This article was originally published in The Pink Sheet Daily

Executive Summary

Some physicians may be concerned by the incidence of osteonecrosis of the jaw reported in pivotal hormone-resistant prostate cancer trial.
Advertisement

Related Content

Xgeva Rejection Shows What’s Needed For Non-Metastatic CRPC Approvals
Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline
Amgen Shifts Its Focus From Products To Pipeline, But Stays In Comfort Zone
Beauty Of Amgen Bone Drug Results Is In Eye Of The Beholder
Amgen Obtains Broader Label For Denosumab With Oncology Indication
Amgen Obtains Broader Label For Denosumab With Oncology Indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS072245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel